Please use this identifier to cite or link to this item:
|Title:||Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies.|
|Authors:||Broadley, Simon A;Barnett, Michael H;Boggild, Mike;Brew, Bruce J;Butzkueven, Helmut;Heard, Robert;Hodgkinson, Suzanne;Kermode, Allan G;Lechner-Scott, Jeannette;Macdonell, Richard A L;Marriott, Mark;Mason, Deborah F;Parratt, John;Reddel, Stephen W;Shaw, Cameron P;Slee, Mark;Spies, Judith;Taylor, Bruce V;Carroll, William M;Kilpatrick, Trevor J;King, John;McCombe, Pamela A;Pollard, John D;Willoughby, Ernest|
|Affiliation:||School of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australia; Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia. Electronic address: firstname.lastname@example.org.|
Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia.
Department of Neurology, The Townsville Hospital, Douglas, QLD, Australia.
Department of Neurology and St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia.
Westmead Clinical School, University of Sydney, NSW, Australia.
South Western Sydney Clinical School, University of New South Wales, NSW, Australia.
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, WA, Australia.
Hunter Medical Research Institute, The University of Newcastle, New Lambton, NSW, Australia.
Department of Neurology, Austin Health, Heidelberg, VIC, Australia.
Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
Central Clinical School, University of Sydney, NSW, Australia.
School of Medicine, Deakin University, VIC, Australia.
Centre for Neuroscience and Flinders Medical Centre, Flinders University, SA, Australia.
Menzies Research Institute, University of Tasmania, TAS, Australia.
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australia.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
University of Queensland Centre for Clinical Research, QLD, Australia.
Department of Neurology, Auckland City Hospital, Auckland, New Zealand.
|Citation:||Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2014; 21(11): 1835-46|
|Abstract:||Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.|
|Internal ID Number:||24993135|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.